Repeating initial MR analyses of VAT on risk of luminal B/HER2-negative-like breast cancer using female-specific data resulted in a different direction of effect than those derived from the primary (ie, sex-combined VAT) analysis. The gene discussed is ERBB2; the disease is breast carcinoma.